These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23961878)

  • 21. Down-regulation of Toll-like receptor 7 expression in hepatitis-virus-related human hepatocellular carcinoma.
    Lin KJ; Lin TM; Wang CH; Liu HC; Lin YL; Eng HL
    Hum Pathol; 2013 Apr; 44(4):534-41. PubMed ID: 23069256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
    Bergmann JF; de Bruijne J; Hotho DM; de Knegt RJ; Boonstra A; Weegink CJ; van Vliet AA; van de Wetering J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Janssen HL; Reesink HW
    Aliment Pharmacol Ther; 2011 Aug; 34(4):443-53. PubMed ID: 21707679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
    Kurimoto A; Hashimoto K; Nakamura T; Norimura K; Ogita H; Takaku H; Bonnert R; McInally T; Wada H; Isobe Y
    J Med Chem; 2010 Apr; 53(7):2964-72. PubMed ID: 20232824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
    Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
    J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist.
    Herberhold S; Coch C; Zillinger T; Hommertgen B; Busch N; Schuberth C; Hartmann E; Wimmenauer V; Hagmann CA; Lüdenbach B; Schlee M; Bootz F; Hartmann G; Barchet W
    Antivir Ther; 2011; 16(5):751-8. PubMed ID: 21817197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect.
    Li S; Yang L; Xu Q; Li X; Zhao J; Tan Z; Gu X; Qiu J
    Eur J Med Chem; 2024 Sep; 275():116575. PubMed ID: 38865744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.
    Mittapalli GK; Zhao F; Jackson A; Gao H; Lee H; Chow S; Kaur MP; Nguyen N; Zamboni R; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4955-61. PubMed ID: 22784640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B.
    Zoulim F; Luangsay S; Durantel D
    Gastroenterology; 2013 Jun; 144(7):1342-4. PubMed ID: 23710602
    [No Abstract]   [Full Text] [Related]  

  • 29. Identification and characterization of a functional, alternatively spliced Toll-like receptor 7 (TLR7) and genomic disruption of TLR8 in chickens.
    Philbin VJ; Iqbal M; Boyd Y; Goodchild MJ; Beal RK; Bumstead N; Young J; Smith AL
    Immunology; 2005 Apr; 114(4):507-21. PubMed ID: 15804288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
    McGowan DC; Herschke F; Khamlichi MD; Rosauro ML; Benedicto SMP; Pauwels F; Stoops B; Pande V; Scholliers A; Van Schoubroeck B; Mostmans W; Van Dijck K; Thoné T; Horton H; Fanning G; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3216-3221. PubMed ID: 30143425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The link between TLR7 signaling and hepatitis B virus infection.
    Sepehri Z; Kiani Z; Alavian SM; Arababadi MK; Kennedy D
    Life Sci; 2016 Aug; 158():63-9. PubMed ID: 27373425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.
    Benson N; de Jongh J; Duckworth JD; Jones HM; Pertinez HE; Rawal JK; van Steeg TJ; Van der Graaf PH
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1179-85. PubMed ID: 20028817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
    Fidock MD; Souberbielle BE; Laxton C; Rawal J; Delpuech-Adams O; Corey TP; Colman P; Kumar V; Cheng JB; Wright K; Srinivasan S; Rana K; Craig C; Horscroft N; Perros M; Westby M; Webster R; van der Ryst E
    Clin Pharmacol Ther; 2011 Jun; 89(6):821-9. PubMed ID: 21451504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
    Nakamura T; Wada H; Kurebayashi H; McInally T; Bonnert R; Isobe Y
    Bioorg Med Chem Lett; 2013 Feb; 23(3):669-72. PubMed ID: 23265901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
    Horsmans Y; Berg T; Desager JP; Mueller T; Schott E; Fletcher SP; Steffy KR; Bauman LA; Kerr BM; Averett DR
    Hepatology; 2005 Sep; 42(3):724-31. PubMed ID: 16116638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
    Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.
    Zhang X; Kraft A; Broering R; Schlaak JF; Dittmer U; Lu M
    Expert Opin Drug Discov; 2012 Jul; 7(7):597-611. PubMed ID: 22607384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
    Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
    Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells.
    Hagelstein J; Kist A; Stremmel W; Galle PR
    Arzneimittelforschung; 1998 Mar; 48(3):343-7. PubMed ID: 9553691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9.
    Hoshino K; Sugiyama T; Matsumoto M; Tanaka T; Saito M; Hemmi H; Ohara O; Akira S; Kaisho T
    Nature; 2006 Apr; 440(7086):949-53. PubMed ID: 16612387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.